Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines
Many studies have shown that the efficacy and risk of side effects of drug treatment is influenced by genetic variants. Evidence based guidelines are essential for implementing pharmacogenetic knowledge in daily clinical practice to optimize pharmacotherapy of individual patients. A literature searc...
Main Authors: | Heshu Abdullah-Koolmees, Antonius M. van Keulen, Marga Nijenhuis, Vera H. M. Deneer |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.595219/full |
Similar Items
-
Variant Interpretation in Current Pharmacogenetic Testing
by: Sally Luvsantseren, et al.
Published: (2020-10-01) -
Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines
by: Lisanne E. N. Manson, et al.
Published: (2020-09-01) -
Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug–Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients
by: Niels Westergaard, et al.
Published: (2020-01-01) -
The Utility of Pharmacogenetic-Guided Psychotropic Medication Selection for Pediatric Patients: A Retrospective Study
by: Merlin Ariefdjohan, et al.
Published: (2021-07-01) -
Pharmacogenomics (PGx) Patient with Mixed Levels of Actionable Variant Evidence
by: Michael J. Schuh, et al.
Published: (2020-05-01)